Skip to main
PSTV
PSTV logo

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc. is advancing its clinical development pipeline, particularly with its lead candidate rhenium (186Re) obisbemeda, which demonstrates promising results in treating central nervous system cancers, showing a 76% radiographic response rate and a mean overall survival of 9 months. Revenue projections for CNSide indicate gradual growth, with expectations of $1 million in 2025 increasing to $38 million by 2032, as the company expands its reach and more users adopt the diagnostic. Additionally, the recent $18 million grant from the Cancer Prevention and Research Institute of Texas underscores Plus Therapeutics's commitment to innovative cancer treatments and supports a long-term positive outlook for the company's financial health and product development trajectory.

Bears say

The negative outlook on Plus Therapeutics Inc. is primarily driven by several factors, including the risks associated with the failure of its product candidates, such as rhenium (186Re) obisbemeda, to demonstrate safety and efficacy in clinical trials. Additionally, challenges in obtaining regulatory approval for commercial sale, securing suitable reimbursement, and facing increased competition further threaten the company's prospects. The recent equity raise has also led to dilution, contributing to the revised 12-month price target being lowered from $3.00 to $2.00 per diluted share.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.